Results 11 to 20 of about 28,210 (101)

EfficientViT: Memory Efficient Vision Transformer with Cascaded Group Attention [PDF]

open access: yesComputer Vision and Pattern Recognition, 2023
Vision transformers have shown great success due to their high model capabilities. However, their remarkable performance is accompanied by heavy computation costs, which makes them unsuitable for real-time applications. In this paper, we propose a family
Xinyu Liu   +5 more
semanticscholar   +1 more source

Rethinking BiSeNet For Real-time Semantic Segmentation [PDF]

open access: yesComputer Vision and Pattern Recognition, 2021
BiSeNet [28], [27] has been proved to be a popular two-stream network for real-time segmentation. However, its principle of adding an extra path to encode spatial information is time-consuming, and the backbones borrowed from pretrained tasks, e.g ...
Mingyuan Fan   +6 more
semanticscholar   +1 more source

PARIS: Part-level Reconstruction and Motion Analysis for Articulated Objects [PDF]

open access: yesIEEE International Conference on Computer Vision, 2023
We address the task of simultaneous part-level reconstruction and motion parameter estimation for articulated objects. Given two sets of multi-view images of an object in two static articulation states, we decouple the movable part from the static part ...
Jiayi Liu, Ali Mahdavi-Amiri, M. Savva
semanticscholar   +1 more source

The impact of AI in physics education: a comprehensive review from GCSE to university levels [PDF]

open access: yesThe Physical Educator, 2023
With the rapid evolution of artificial intelligence (AI), its potential implications for higher education have become a focal point of interest.
W. Yeadon, Tom Hardy
semanticscholar   +1 more source

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

open access: yesJournal of Clinical Oncology, 2023
PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies.
P. H. O'Donnell   +24 more
semanticscholar   +1 more source

MathCoder: Seamless Code Integration in LLMs for Enhanced Mathematical Reasoning [PDF]

open access: yesInternational Conference on Learning Representations, 2023
The recently released GPT-4 Code Interpreter has demonstrated remarkable proficiency in solving challenging math problems, primarily attributed to its ability to seamlessly reason with natural language, generate code, execute code, and continue reasoning
Ke Wang   +9 more
semanticscholar   +1 more source

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

open access: yesClinical Infectious Diseases, 2020
Background Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. This study aimed to clarify the characteristics of patients with refractory COVID-19.
Pingzheng Mo   +18 more
semanticscholar   +1 more source

Dispelling the Digital Enchantment: how can we move beyond its destructive influence and reclaim our right to an open future?

open access: yesPrometheus, 2023
This paper outlines the content and contours of a fictional tale called the ‘Digital Enchantment’, based on the author’s observations and experience of high-level policy discussions concerning digital policy and regulation as an academic lawyer with ...
Karen Yeung
doaj   +1 more source

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

open access: yesEClinicalMedicine, 2020
Background A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings.
Hannah E. Davis   +8 more
semanticscholar   +1 more source

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy